Company Filing History:
Years Active: 2014-2020
Introduction
Sheeno Thyparambil is a distinguished inventor based in Frederick, Maryland, known for his significant contributions to the field of cancer diagnostics. With an impressive portfolio of 29 patents, his work focuses on the advancement of innovative methodologies for quantifying important cancer biomarkers.
Latest Patents
Among his latest innovations are two pivotal patents that enhance cancer evaluation techniques. The first patent details a **Multiplex MRM assay for evaluation of cancer**, which provides specific peptides and their ionization characteristics from the estrogen receptor (ER), progesterone receptor (PR), and antigen Ki67 (Ki67) proteins. This assay utilizes Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry to quantify these proteins directly in formalin-fixed biological samples, including various tissue types.
The second patent pertains to the **SRM/MRM assay for the fibroblast growth factor receptor 2 (FGFR2) protein**, offering methods to quantify FGFR2 in similar fixed biological samples. Both patents significantly improve the analytical capabilities for cancer research, allowing scientists to obtain crucial insights from chemically preserved biological specimens.
Career Highlights
Throughout his career, Sheeno has held key positions at prominent companies such as Expression Pathology Incorporated and Expression Pathology, Inc. His experience in these firms has bolstered his expertise in developing cutting-edge diagnostic tools that support cancer detection and management.
Collaborations
Sheeno has collaborated with notable figures in the scientific community, including coworkers David B. Krizman and Todd Hembrough. These collaborations have played an essential role in the development of his patents and reflect his dedication to advancing research in oncology.
Conclusion
In conclusion, Sheeno Thyparambil stands out as a pioneering inventor whose work in cancer diagnostics has made significant contributions to medical science. His innovative patents reflect his commitment to improving healthcare outcomes through advanced analytical methods, thereby enhancing the understanding and treatment of cancer.